REGN Overview
Upcoming Projects (REGN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (REGN)
-
Third View: Discussing recent approval for first biologic treatment of COPD with Dupixent.
Ticker: REGN
Executed On: Nov 13, 2024 at 11:00 AM EST -
Second View: Discussing recent approval for first biologic treatment of COPD with Dupixent.
Ticker: REGN
Executed On: Nov 06, 2024 at 05:00 PM EST -
Discussing recent approval for first biologic treatment of COPD with Dupixent.
Ticker: REGN
Executed On: Oct 21, 2024 at 04:30 PM EDT -
A Third Opinion: Reviewing the current clinical landscape for wet-AMD and the potential of Roche's Susvimo
Tickers: RHHBY, REGN
Executed On: Jul 18, 2024 at 08:15 AM EDT -
A Second Opinion: Reviewing the current clinical landscape for wet-AMD and the potential of Roche's Susvimo
Tickers: RHHBY, REGN
Executed On: Jul 15, 2024 at 03:00 PM EDT -
Reviewing the current clinical landscape for wet-AMD and the potential of Roche's Susvimo
Tickers: RHHBY, REGN
Executed On: Jul 12, 2024 at 02:00 PM EDT -
A Third Look: Checking in with a prescriber of retinal disease treatments Eylea and Vabysmo.
Tickers: REGN, RHHBY
Executed On: May 23, 2024 at 05:00 PM EDT -
A Third Look: Discussing the potential of Dupixent (dupilumab) for COPD and the recent updated results from the Phase 3 trial published on May 20th.
Tickers: REGN, SNY
Executed On: May 23, 2024 at 03:00 PM EDT -
A Second Look: Discussing the potential of Dupixent (dupilumab) for COPD and the results from the Phase 3 NOTUS trial.
Tickers: REGN, SNY
Executed On: May 21, 2024 at 09:00 AM EDT -
Discussing the potential of Dupixent (dupilumab) for COPD and the results from the Phase 3 NOTUS trial.
Tickers: REGN, SNY
Executed On: May 13, 2024 at 01:00 PM EDT -
A Second Look: Checking in with a prescriber of retinal disease treatments Eylea and Vabysmo.
Tickers: REGN, RHHBY
Executed On: May 08, 2024 at 09:00 AM EDT -
Checking in with a prescriber of retinal disease treatments Eylea and Vabysmo.
Tickers: REGN, RHHBY
Executed On: May 07, 2024 at 04:30 PM EDT -
A look at Regeneron's investigational BCMA×CD3 bispecific antibody, Linvoseltamab, and the results from the Linker-MM1 Study of Linvoseltamab in multiple myeloma presented at the ASH conference.
Ticker: REGN
Executed On: Dec 21, 2023 at 03:00 PM EST -
A Third Opinion: Discussing the standard of care and/or the potential of Vabysmo (faricimab-svoa) and the recent label expansion approved by the FDA to include treatment of RVO
Tickers: RHHBY, REGN
Executed On: Nov 29, 2023 at 06:00 PM EST -
A Second Opinion: Discussing the standard of care and/or the potential of Vabysmo (faricimab-svoa) and the recent label expansion approved by the FDA to include treatment of RVO
Tickers: RHHBY, REGN
Executed On: Nov 15, 2023 at 10:00 AM EST -
Discussing the standard of care and/or the potential of Vabysmo (faricimab-svoa) and the recent label expansion approved by the FDA to include treatment of RVO
Tickers: RHHBY, REGN
Executed On: Nov 02, 2023 at 09:00 AM EDT -
Discussing the potential of high dose aflibercept (Eylea)
Tickers: REGN, NVS
Executed On: Sep 14, 2023 at 03:30 PM EDT -
A Third Look: Examining how Kevzara® (sarilumab) fits into the treatment landscape for treating patients with Polymyalgia Rheumatica (PMR)
Tickers: REGN, SNY
Executed On: Aug 31, 2023 at 12:00 PM EDT -
A Second Look: Examining how Kevzara® (sarilumab) fits into the treatment landscape for treating patients with Polymyalgia Rheumatica (PMR)
Tickers: REGN, SNY
Executed On: Aug 30, 2023 at 04:00 PM EDT -
Examining how Kevzara® (sarilumab) fits into the treatment landscape for treating patients with Polymyalgia Rheumatica (PMR)
Tickers: REGN, SNY
Executed On: Aug 25, 2023 at 05:00 PM EDT -
Discussing the potential of aflibercept (Eylea) biosimilars and specifically speaking on the Mylight clinical study from Sandoz and Novartis
Tickers: NVS, REGN
Executed On: Aug 23, 2023 at 05:00 PM EDT -
Discussing the recent label expansion Evkeeza (Evinacumab) by Regeneron to include children ages 5 to 11 years with rare homozygous familial hypercholesterolemia (HoFH)
Ticker: REGN
Executed On: Jun 01, 2023 at 12:45 PM EDT -
A third look: Digging into the potential of Dupixent (dupilumab) in patients with COPD and the positive results from the Phase 3 BOREAS trial
Tickers: REGN, SNY
Executed On: Apr 06, 2023 at 06:00 PM EDT -
A second look: Digging into the potential of Dupixent (dupilumab) in patients with COPD and the positive results from the Phase 3 BOREAS trial
Tickers: REGN, SNY
Executed On: Mar 31, 2023 at 10:00 AM EDT -
Digging into the potential of Dupixent (dupilumab) in patients with COPD and the positive results from the Phase 3 BOREAS trial
Tickers: REGN, SNY
Executed On: Mar 30, 2023 at 04:00 PM EDT -
A second discussion on EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Tickers: EYPT, FDMT, RHHBY, REGN
Executed On: Mar 03, 2023 at 12:30 PM EST -
Discussing EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Tickers: EYPT, FDMT, RHHBY, REGN
Executed On: Mar 01, 2023 at 05:30 PM EST -
Reviewing the phase 1/2 clinical trial results of 4D Molecular Therapeutics' 4D-150, a potential gene therapy for patients with wet-AMD
Tickers: FDMT, RHHBY, REGN
Executed On: Jan 24, 2023 at 02:00 PM EST -
Discussing the potential of Odronextamab, a CD20xCD3 bispecific antibody and the results from it's Phase II ELM-2 study in patients with Relapsed/Refractory DLBCL highlighted at ASH 2022
Ticker: REGN
Executed On: Dec 21, 2022 at 09:00 AM EST -
A Second look at the new approval for Dupixent in treating prurigo nodularis
Tickers: SNY, REGN
Executed On: Dec 02, 2022 at 10:00 AM EST -
A First look at the new approval for Dupixent in treating prurigo nodularis
Tickers: SNY, REGN
Executed On: Nov 30, 2022 at 02:00 PM EST -
A third look at the P1 data presented at ESMO for ubamatamab, a CD3-targeting bispecific antibody under investigation for recurrent ovarian cancer
Ticker: REGN
Executed On: Oct 27, 2022 at 09:30 AM EDT -
A First look at Regeneron's Libtayo (cemiplimab) and Fianlimab (LAG-3 inhibitor) combo as a novel treatment for melanoma
Ticker: REGN
Executed On: Oct 13, 2022 at 11:00 AM EDT -
Discussing the P1 data presented at ESMO for ubamatamab, a CD3-targeting bispecific antibody under investigation for recurrent ovarian cancer
Ticker: REGN
Executed On: Sep 29, 2022 at 03:00 PM EDT -
An in depth discussion of the clinical landscape for Macular Edema, with a close look at Eylea and Regeneron's new data on its higher dosing versions
Ticker: REGN
Executed On: Sep 27, 2022 at 07:00 PM EDT -
Discussing the pros/cons of Ebanga (Ansuvimab) and Inmazeb as a therapeutic agent for ebola
Ticker: REGN
Executed On: Sep 20, 2022 at 03:00 PM EDT -
A second in depth discussion of the clinical landscape for Macular Edema, with a close look at the phase 3 results of Kodiak Sciences tarcocimab and its potential in this space.
Tickers: KOD, REGN
Executed On: Sep 08, 2022 at 08:00 AM EDT -
An in depth discussion of the clinical landscape for Macular Edema, with a close look at the phase 3 results of Kodiak Sciences tarcocimab and its potential in this space.
Tickers: KOD, REGN
Executed On: Sep 02, 2022 at 11:00 AM EDT -
A Fourth View: Examining the potential of Haduvio in prurigo nodularis with a focus on the recent data from the P2b/3 PRISM trial
Tickers: TRVI, REGN, SNY
Executed On: Aug 30, 2022 at 12:00 PM EDT -
A Third View: Examining the potential of Haduvio in prurigo nodularis with a focus on the recent data from the P2b/3 PRISM trial
Tickers: TRVI, REGN, SNY
Executed On: Aug 22, 2022 at 12:00 PM EDT -
A Second View: Discussing the use of Cemdisiran in patients with Immunoglobulin A Nephropathy (IgAN)
Tickers: ALNY, REGN
Executed On: Aug 22, 2022 at 10:00 AM EDT -
A Second View: Examining the potential of Haduvio in prurigo nodularis with a focus on the recent data from the P2b/3 PRISM trial
Tickers: TRVI, SNY, REGN
Executed On: Aug 17, 2022 at 10:00 AM EDT -
Discussing the use of Cemdisiran in patients with Immunoglobulin A Nephropathy (IgAN)
Tickers: ALNY, REGN
Executed On: Jul 22, 2022 at 09:00 AM EDT -
A third look at Dupixent's recent FDA approval for its new indication of EoE and the Phase 3 study(NCT03633617)
Ticker: REGN
Executed On: Jun 28, 2022 at 03:00 PM EDT -
A second look at Dupixent's recent FDA approval for its new indication of EoE and the Phase 3 study(NCT03633617)
Ticker: REGN
Executed On: Jun 24, 2022 at 11:00 AM EDT -
A look at Dupixent's recent FDA approval for its new indication of EoE and the Phase 3 study(NCT03633617)
Ticker: REGN
Executed On: Jun 16, 2022 at 04:45 PM EDT -
A Second View: Examining the potential of Evkeeza (evinacumab) as a new treatment option for patients with Homozygous Familial Hypercholesterolemia (HoFH)
Tickers: REGN, RARE
Executed On: Mar 23, 2022 at 09:00 AM EDT -
Examining the potential of Evkeeza (evinacumab) as a new treatment option for patients with Homozygous Familial Hypercholesterolemia (HoFH)
Tickers: REGN, RARE
Executed On: Feb 24, 2022 at 11:00 AM EST
Upcoming & Overdue Catalysts (REGN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (REGN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
